Yury Kukushkin became a Managing Director for the T1D Fund in 2022 after joining as an Investment Director in 2019 from 4BIO Capital, a London-based fund investing in public and private life sciences companies. While there, he focused on gene and cell therapies, PROTACs, RNA medicines, and targeted therapies and delivered top quartile returns for the fund. Prior to this role, Yury was Chief Analyst and Associate at RBV Capital, an early-stage life sciences venture fund. Earlier in his career, Yury worked in various roles in a boutique consulting company Abercade supporting over 20 various investment deals with US-based venture-backed companies.